Araştırma Makalesi
Yıl 2023,
Cilt: 9 Sayı: 5 - September 2023, 1149 - 1156, 04.09.2023
Öz
Kaynakça
- 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-10.
- 2. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321:2003-17.
- 3. Gavelli F, Castello LM, Avanzi GC. Management of sepsis and septic shock in the emergency department. Intern Emerg Med 2021;16:1649-61.
- 4. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011;32:569-80.
- 5. Villa-Hermosilla MC, Negro S, Barcia E, Hurtado C, Montejo C, Alonso M, et al. Celecoxib microparticles for inhalation in COVID-19-related acute respiratory distress syndrome. Pharmaceutics 2022;14:1392.
- 6. Senousy SR, El-Daly M, Ibrahim ARN, Khalifa MMA, Ahmed AF. Effect of celecoxib and infliximab against multiple organ damage induced by sepsis in rats: a comparative study. Biomedicines 2022;10:1613.
- 7. Scott J, Ruchaud-Sparagano MH, Musgrave K, Roy AI, Wright SE, Perry JD, et al. Phosphoinositide 3-kinase δ inhibition improves neutrophil bacterial killing in critically Ill patients at high risk of infection. J Immunol 2021;207:1776-84.
- 8. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
- 9. Wood AJ, Vassallo AM, Ruchaud-Sparagano MH, Scott J, Zinnato C, Gonzalez-Tejedo C, et al. C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. JCI Insight 2020;5:e137029.
- 10. Shaw TD, McAuley DF, O’Kane CM Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs 2019;24:29-41.
- 11. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010;23:243-52.
- 12. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res 2019;6:e000420.
- 13. Alsaegh H, Eweis H, Kamal F, Alrafiah A. Celecoxib decrease seizures susceptibility in a rat model of inflammation by inhibiting HMGB1 translocation. Pharmaceuticals (Basel) 2021;14:380.
- 14. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev 2017;5:CD009865
- 15. Karaali R, Saylav Bora E, Acar H, Uyanikgil Y, Sever IH, Erdogan MA, et al. Exploring beta blockers’ efficacy in sepsis-induced acute lung injury and HMGB1-sRAGE interaction. Int J Pharmacol 2023;19: 296-304.
- 16. Kwon WY, Suh GJ, Kim KS, Kwak YH. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-[kappa]B pathway. Crit Care Med 2011;39:328-34.
- 17. Liu D, Wang Y, Li L, Zhao H, Li L, Liu Y, et al. Celecoxib protects hyperoxia-induced lung injury via NF-κB and AQP1. Front Pediatr 2019;7:228.
- 18. Mazhari S, Razi M, Sadrkhanlou R. Silymarin and Celecoxib ameliorate experimental varicocele-induced pathogenesis: evidence for oxidative stress and inflammation inhibition. Int Urol nephrol 2018;50:1039-52.
- 19. Gurusamy M, Nasseri S, Rampa DR, Feng H, Lee D, Pekcec A, et al. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. J Transl Med 2021;19:340.
- 20. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
- 21. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2012;9(2 Suppl):28-35.
- 22. Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, et al. Induction of claudin-4 by non-steroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 2005;65:1868-76.
- 23. Short SS, Wang J, Castle SL, Fernandez GE, Smiley N, Zobel M, et al. Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis. Lab Invest 2013;93:1265-75.
Yıl 2023,
Cilt: 9 Sayı: 5 - September 2023, 1149 - 1156, 04.09.2023
Öz
Objectives: This experimental study investigated the preventive effects of Celecoxib, a selective COX-2 inhibitor, on lung injury induced by intra-abdominal sepsis in rats. The study assessed Celecoxib's potential to mitigate the harmful impacts of sepsis on lung tissue.
Methods: Thirty male Wistar albino rats, divided into three groups: a normal control group, a sepsis-induced group treated with saline, and a sepsis-induced group treated with Celecoxib. Sepsis was induced using fecal intraperitoneal injection (FIP), followed by a one-hour administration of Celecoxib at 50 mg/kg/day to the treatment group. Biochemical analysis of lung tissue measured oxidative stress markers (malondialdehyde [MDA]) and pro-inflammatory cytokines (Tumor Necrosis Faftor-α [TNF-α]). Histopathological examination evaluated lung tissue damage, encompassing alveolar congestion, hemorrhage, inflammatory cell aggregation, and edema. Arterial blood gas analysis quantified partial oxygen (PaO2) and carbon dioxide (PaCO2) pressures.
Results: Celecoxib-treated rats exhibited reduced oxidative stress markers with lower MDA levels, indicating decreased oxidative damage in lung tissue. Moreover, TNF-α and other pro-inflammatory cytokines were significantly reduced in lung tissues of Celecoxib-treated rats, indicating its anti-inflammatory effects. Histopathological examination revealed reduced lung tissue damage in Celecoxib-treated rats, including alveolar congestion, hemorrhage, and inflammatory cell aggregation. Arterial blood gas analysis showed improved oxygenation (PaO2) in the Celecoxib-treated group compared to untreated sepsis rats.
Conclusions: Celecoxib demonstrated preventive effects against sepsis-induced lung injury in rats by mitigating oxidative stress and inflammation, thereby preserving lung tissue integrity—further research, including clinical trials, to validate its effectiveness and safety in human sepsis management.
Anahtar Kelimeler
Kaynakça
- 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-10.
- 2. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321:2003-17.
- 3. Gavelli F, Castello LM, Avanzi GC. Management of sepsis and septic shock in the emergency department. Intern Emerg Med 2021;16:1649-61.
- 4. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011;32:569-80.
- 5. Villa-Hermosilla MC, Negro S, Barcia E, Hurtado C, Montejo C, Alonso M, et al. Celecoxib microparticles for inhalation in COVID-19-related acute respiratory distress syndrome. Pharmaceutics 2022;14:1392.
- 6. Senousy SR, El-Daly M, Ibrahim ARN, Khalifa MMA, Ahmed AF. Effect of celecoxib and infliximab against multiple organ damage induced by sepsis in rats: a comparative study. Biomedicines 2022;10:1613.
- 7. Scott J, Ruchaud-Sparagano MH, Musgrave K, Roy AI, Wright SE, Perry JD, et al. Phosphoinositide 3-kinase δ inhibition improves neutrophil bacterial killing in critically Ill patients at high risk of infection. J Immunol 2021;207:1776-84.
- 8. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
- 9. Wood AJ, Vassallo AM, Ruchaud-Sparagano MH, Scott J, Zinnato C, Gonzalez-Tejedo C, et al. C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. JCI Insight 2020;5:e137029.
- 10. Shaw TD, McAuley DF, O’Kane CM Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs 2019;24:29-41.
- 11. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010;23:243-52.
- 12. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res 2019;6:e000420.
- 13. Alsaegh H, Eweis H, Kamal F, Alrafiah A. Celecoxib decrease seizures susceptibility in a rat model of inflammation by inhibiting HMGB1 translocation. Pharmaceuticals (Basel) 2021;14:380.
- 14. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev 2017;5:CD009865
- 15. Karaali R, Saylav Bora E, Acar H, Uyanikgil Y, Sever IH, Erdogan MA, et al. Exploring beta blockers’ efficacy in sepsis-induced acute lung injury and HMGB1-sRAGE interaction. Int J Pharmacol 2023;19: 296-304.
- 16. Kwon WY, Suh GJ, Kim KS, Kwak YH. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-[kappa]B pathway. Crit Care Med 2011;39:328-34.
- 17. Liu D, Wang Y, Li L, Zhao H, Li L, Liu Y, et al. Celecoxib protects hyperoxia-induced lung injury via NF-κB and AQP1. Front Pediatr 2019;7:228.
- 18. Mazhari S, Razi M, Sadrkhanlou R. Silymarin and Celecoxib ameliorate experimental varicocele-induced pathogenesis: evidence for oxidative stress and inflammation inhibition. Int Urol nephrol 2018;50:1039-52.
- 19. Gurusamy M, Nasseri S, Rampa DR, Feng H, Lee D, Pekcec A, et al. Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice. J Transl Med 2021;19:340.
- 20. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
- 21. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2012;9(2 Suppl):28-35.
- 22. Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, et al. Induction of claudin-4 by non-steroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 2005;65:1868-76.
- 23. Short SS, Wang J, Castle SL, Fernandez GE, Smiley N, Zobel M, et al. Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis. Lab Invest 2013;93:1265-75.
Toplam 23 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Genel Cerrahi |
| Bölüm | Original Article |
| Yazarlar | |
| Erken Görünüm Tarihi | 21 Ağustos 2023 |
| Yayımlanma Tarihi | 4 Eylül 2023 |
| Gönderilme Tarihi | 26 Temmuz 2023 |
| Kabul Tarihi | 19 Ağustos 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 9 Sayı: 5 - September 2023 |
e-ISSN: 2149-3189
The European Research Journal, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2024